“Dipan Mehta advises investors to be overweight on the broader pharma sector. While acknowledging the good opportunity in GLP-1, he cautions about too many players, and suggests that CDMO companies, having seen sharp corrections, should be on investor watchlists for a potential turnaround.”
Dipan Mehta’s track record: 12 graded calls · 95% CI 25–75%
Nifty PharmaBullishCalled 26 Feb 2026Graded 19 Jul 2026
Nifty Pharma declined from ₹22952.35 to ₹22232.25, a decrease of 3.14% over 30 days, which contradicts the bullish overweight advice.
Read the original articleSee Dipan Mehta’s full track record